Sio Capital Gains An Impressive 23.3% In 2018 As Biotech Shorts Pay Off: Here Are The Companies That They Are Betting Against

Rupert Hargreaves

Published onFebruary 25, 2019

Updated on February 25, 2019

Sio Capital Management, the healthcare-focused long/short equity hedge fund achieved an outstanding outperformance for its partners in 2018.

Q4 hedge fund letters, conference, scoops etc

According to a copy of the firm's full-year letter, which has been reviewed by ValueWalk, Sio returned 23.3% net in 2018. These returns compare with returns of -4.4% for the S&P 500 Total Return Index, 1.0% for the MSCI World Healthcare Index, and -10.4% for the MSCI World Index.

If you’re looking for value stocks, and exclusive access to value-focused hedge fund managers, check out ValueWalk’s exclusive value newsletter, Hidden Value Stocks. Use code 15percent10 at checkout. Offer valid for next 10 subscribers or March 31, 2019 whichever comes first!

Login required to continue reading.

Setup a free account to get access to this article (no credit card required).

View Full Article

Already a member? Log in here

Rupert Hargreaves

Sign up now and get our in-depth FREE e-books on famous investors like Klarman, Dalio, Schloss, Munger Rupert is a committed value investor and regularly writes and invests following the principles set out by Benjamin Graham. He is the editor and co-owner of Hidden Value Stocks, a quarterly investment newsletter aimed at institutional investors. Rupert owns shares in Berkshire Hathaway. Rupert holds qualifications from the Chartered Institute For Securities & Investment and the CFA Society of the UK. Rupert covers everything value investing for Hedge Fund Alpha

Sio Capital Gains An Impressive 23.3% In 2018 As Biotech Shorts Pay Off: Here Are The Companies That They Are Betting Against

Login required to continue reading.

Get Your Business News